Patients with cancer and hospital admissions: disease trajectory and strategic choices.

cancer end of life care hospital care prognosis symptoms and symptom management

Journal

BMJ supportive & palliative care
ISSN: 2045-4368
Titre abrégé: BMJ Support Palliat Care
Pays: England
ID NLM: 101565123

Informations de publication

Date de publication:
13 Sep 2023
Historique:
received: 25 08 2023
accepted: 28 08 2023
medline: 14 9 2023
pubmed: 14 9 2023
entrez: 13 9 2023
Statut: aheadofprint

Résumé

Hospital admission (HA) in cancer history is a common, repeated and frequently unplanned event. The emergency departments (EDs) and the oncological outpatient service (OOS) are the ordinary way of entry. We studied the reasons of admission, pathways of access and discharge and prognostic factors in a population of admitted patients with cancer. The health records of the admitted patients in the oncological ward of a referral hospital in a 6-month period were retrieved and analysed. The characteristics of those admitted in the last 3 months of life were compared with the other group. Among the 147 HA, 79.5% were unplanned, 48.9% passing through the ED and 30.6% through the OOS; 56.5% were due to cancer-related symptoms; 50.3% occurred in the last 3 months of life. Median overall survival was 90 days (95% IC 53.1-126.9). Independent prognostic factors for survival were: being admitted for symptoms, referral through the ED and not being discharged at home. Hospital is a turning point in the cancer care pathway. Patients needing HA have a dismal prognosis, half of them being in the last 3 months of life. This group can be identified using universally available variables.

Identifiants

pubmed: 37704262
pii: spcare-2023-004574
doi: 10.1136/spcare-2023-004574
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Gianmauro Numico (G)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy numico.g@ospedale.cuneo.it.

Rachele Ferrua (R)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Elena Fea (E)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Jacopo Giamello (J)

Emergency Medicine, AO S.Croce e Carle, Cuneo, Italy.

Ida Colantonio (I)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Marcella Occelli (M)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Anna Maria Vandone (AM)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Paola Vanella (P)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Giacomo Aimar (G)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Chiara Pisano (C)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Elena Parlagreco (E)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Irene Persano (I)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Michela Milanesio (M)

Medical Oncology, AO S.Croce e Carle, Cuneo, Italy.

Roberto Ippoliti (R)

Department of Jurisprudence and Political Economic and Social Sciences, University of Eastern Piedmont Amedeo Avogadro, Alessandria, Piemonte, Italy.

Classifications MeSH